SCHEMBL24287240

SCHEMBL24287240

Cc1nc(Oc2ccccc2C)c2c(n1)-c1ccccc1CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ LMNA P02545 3/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ ATM Q13315 2/20 0.42
▸ BCHE P06276 2/20 0.41
▸ ACHE P22303 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ HRH4 Q9H3N8 3/20 0.39
▸ HRH1 P35367 2/20 0.39
▸ HRH2 P25021 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39
▸ KDM4E B2RXH2 7/20 0.39
▸ ALDH1A1 P00352 5/20 0.39
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24287411 0.87 HRH4 (0.51) MAPTL3MBTL1LMNAMEN1KMT2A
SCHEMBL26813159 0.85 LMNA (0.39) MAPTL3MBTL1LMNAMEN1KMT2A
SCHEMBL26813383 0.72 HTR1A (0.40) HRH4HRH1HRH2HRH3KDM4E
SCHEMBL19700977 0.71 BCHE (0.53) MAPTL3MBTL1LMNAMEN1KMT2A
SCHEMBL24287268 0.68 TP53 (0.40) L3MBTL1LMNAMEN1KMT2AHPGD
SCHEMBL24287267 0.67 TP53 (0.40) LMNAMEN1KMT2AHPGDBCHE
SCHEMBL11865968 0.66 NPC1 (0.53) BCHEACHENPC1RAB9ADYRK1A
SCHEMBL26813286 0.66 BCHE (0.38) MAPTLMNAMEN1KMT2AHPGD
SCHEMBL13200326 0.65 DYRK1A (0.50) MAPTLMNAMEN1KMT2AHPGD
SCHEMBL25473538 0.65 ADORA1 (0.49) MAPTMEN1KMT2ABCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373974-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076629-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373974-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B MAPT 4871/4885L3MBTL1 4306/4885LMNA 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback